Filing Flows › Acadia Pharmaceuticals (ACAD) › Guidance & outlook

Acadia Pharmaceuticals (ACAD) guidance and outlook

Acadia Pharmaceuticals (ACAD) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $1.3B for FY2026. Acadia Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 20 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 4, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• In order to achieve significant long-term growth, we plan to develop our current portfolio, expand our pipeline of early- and late-stage product candidates and expand into areas of rare disease that are adjacent to our existing franchises, including through strategic business development, and make use of our internal capabilities and knowledge.
• Therefore, we plan to continue enrolling our two ongoing Phase 3 studies evaluating remlifanserin for the once daily 60 mg dose in ADP while implementing amendments to the Phase 3 program, including removing the once daily 30 mg dosage arm.
• We initiated an additional Phase 2 study of remlifanserin in LBDP in September 2025 and expect a data readout in the fourth quarter 2027.
• In the fourth quarter of 2025, we initiated a Phase 2 study of ACP-211 for the treatment of major depressive disorder and expect a data readout in the second half 2027.
• We also expect to incur increased research and development expenses as a result of advancement of our early-stage product candidates.
• Historically, we have used our internal research and development resources, including our employees and discovery infrastructure, across several projects and many of our costs have not been attributable to a specific project.
• Accordingly, we have not reported our internal research and development costs on a project-by-project basis.
• At this time, due to the risks inherent in regulatory requirements and clinical development, we are unable to estimate with certainty the costs we will incur to support the commercialization of DAYBUE products, as well as the further development of our product candidates.
• Likewise, we are unable to determine with certainty the anticipated completion dates for our current research and development programs.
• While our current development efforts are primarily focused on advancing the development of remlifanserin and early-stage product candidates, we anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the scientific and clinical success of each product candidate, as well as an ongoing assessment of the commercial…
• We cannot forecast with any degree of certainty which product candidates will be subject to future collaborative or licensing arrangements, when such arrangements will be secured, if at all, and to what degree any such arrangements would affect our development plans and capital requirements.
• We expect our research and development expenses will continue to be substantial as we conduct studies pursuant to our PMRs and pursue the further development of remlifanserin and early-stage product candidates.

Acadia Pharmaceuticals' latest quarter

Questions

Did Acadia Pharmaceuticals raise or lower its guidance?

Acadia Pharmaceuticals (ACAD) raised some and lowered other parts of its guidance on Nov 4, 2026: Revenue $1.3B for FY2026.

What does Acadia Pharmaceuticals expect?

In order to achieve significant long-term growth, we plan to develop our current portfolio, expand our pipeline of early- and late-stage product candidates and expand into areas of rare disease that are adjacent to our existing franchises, including through strategic business development, and make use of our internal capabilities and knowledge. Therefore, we plan to continue enrolling our two ongoing Phase 3 studies evaluating remlifanserin for the once daily 60 mg dose in ADP while implementing amendments to the Phase 3 program, including removing the once daily 30 mg dosage arm. We initiated

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.